3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
5
Waldenstrom Macroglobulinemia
1
Recurrence
1
Precancerous Conditions
1
Neoplasms, Plasma Cell
1
Medulloblastoma
1
Mastocytosis, Systemic
1
Lymphoma, Mantle-Cell
1
Liver Neoplasms
1
Leukemia, Large Granular Lymphocytic
1
Ependymoma
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
51
fludarabine
37
Dexamethasone
35
venetoclax
30
pembrolizumab
25
Rituximab
20
pomalidomide
18
Lenalidomide
17
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
12
carfilzomib
11
Temozolomide
11
Injections
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Cisplatin
9
Bortezomib
9
Azacitidine
9
selinexor
8
Vincristine
8
Immunotherapy, Adoptive
8
obinutuzumab
7
cemiplimab
7
Drug Therapy
7
Carboplatin
7
zanubrutinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Thalidomide
×
1 year
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled